- Home
- INVE vs APLT Comparison
INVE vs APLT Comparison
Compare INVE & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- APLT
- Stock Information
- Founded
- INVE 1990
- APLT 2016
- Country
- INVE United States
- APLT United States
- Employees
- INVE N/A
- APLT N/A
- Industry
- INVE Computer peripheral equipment
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- APLT Health Care
- Exchange
- INVE Nasdaq
- APLT Nasdaq
- Market Cap
- INVE 85.9M
- APLT 63.6M
- IPO Year
- INVE 1997
- APLT 2019
- Fundamental
- Price
- INVE $3.66
- APLT $0.41
- Analyst Decision
- INVE Strong Buy
- APLT Buy
- Analyst Count
- INVE 2
- APLT 6
- Target Price
- INVE $5.50
- APLT $6.10
- AVG Volume (30 Days)
- INVE 37.8K
- APLT 771.9K
- Earning Date
- INVE 11-06-2025
- APLT 11-06-2025
- Dividend Yield
- INVE N/A
- APLT N/A
- EPS Growth
- INVE N/A
- APLT N/A
- EPS
- INVE 3.12
- APLT N/A
- Revenue
- INVE $23,538,000.00
- APLT $121,000.00
- Revenue This Year
- INVE N/A
- APLT N/A
- Revenue Next Year
- INVE $9.98
- APLT $5,931.24
- P/E Ratio
- INVE $1.19
- APLT N/A
- Revenue Growth
- INVE N/A
- APLT N/A
- 52 Week Low
- INVE $2.86
- APLT $0.30
- 52 Week High
- INVE $4.29
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- INVE 49.91
- APLT 38.50
- Support Level
- INVE $3.58
- APLT $0.40
- Resistance Level
- INVE $3.85
- APLT $0.46
- Average True Range (ATR)
- INVE 0.14
- APLT 0.03
- MACD
- INVE -0.02
- APLT -0.01
- Stochastic Oscillator
- INVE 25.00
- APLT 7.74
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.